509 related articles for article (PubMed ID: 27009868)
1. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
Leiter LA; Cefalu WT; de Bruin TW; Xu J; Parikh S; Johnsson E; Gause-Nilsson I
Diabetes Obes Metab; 2016 Aug; 18(8):766-74. PubMed ID: 27009868
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time.
Parikh S; Wilding J; Jabbour S; Hardy E
Int J Clin Pract; 2015 Feb; 69(2):186-98. PubMed ID: 25438821
[TBL] [Abstract][Full Text] [Related]
3. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.
Del Prato S; Nauck M; Durán-Garcia S; Maffei L; Rohwedder K; Theuerkauf A; Parikh S
Diabetes Obes Metab; 2015 Jun; 17(6):581-590. PubMed ID: 25735400
[TBL] [Abstract][Full Text] [Related]
4. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
[TBL] [Abstract][Full Text] [Related]
5. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
Nauck MA; Del Prato S; Durán-García S; Rohwedder K; Langkilde AM; Sugg J; Parikh SJ
Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
Cefalu WT; Leiter LA; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ
Diabetes Care; 2015 Jul; 38(7):1218-27. PubMed ID: 25852208
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.
Kaku K; Kiyosue A; Inoue S; Ueda N; Tokudome T; Yang J; Langkilde AM
Diabetes Obes Metab; 2014 Nov; 16(11):1102-10. PubMed ID: 24909293
[TBL] [Abstract][Full Text] [Related]
10. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S16-26. PubMed ID: 23529567
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
Fioretto P; Mansfield TA; Ptaszynska A; Yavin Y; Johnsson E; Parikh S
Drugs Aging; 2016 Jul; 33(7):511-22. PubMed ID: 27357173
[TBL] [Abstract][Full Text] [Related]
12. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
Weber MA; Mansfield TA; Alessi F; Iqbal N; Parikh S; Ptaszynska A
Blood Press; 2016; 25(2):93-103. PubMed ID: 26623980
[TBL] [Abstract][Full Text] [Related]
13. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes.
Matthaei S; Bowering K; Rohwedder K; Sugg J; Parikh S; Johnsson E;
Diabetes Obes Metab; 2015 Nov; 17(11):1075-84. PubMed ID: 26212528
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
Leiter LA; Cefalu WT; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ
J Am Geriatr Soc; 2014 Jul; 62(7):1252-62. PubMed ID: 24890683
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.
Kaku K; Inoue S; Matsuoka O; Kiyosue A; Azuma H; Hayashi N; Tokudome T; Langkilde AM; Parikh S
Diabetes Obes Metab; 2013 May; 15(5):432-40. PubMed ID: 23194084
[TBL] [Abstract][Full Text] [Related]
16. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
Dekkers CCJ; Wheeler DC; Sjöström CD; Stefansson BV; Cain V; Heerspink HJL
Nephrol Dial Transplant; 2018 Nov; 33(11):2005-2011. PubMed ID: 29370424
[TBL] [Abstract][Full Text] [Related]
17. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
Nauck M; del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S6-15. PubMed ID: 23529570
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure.
Kosiborod M; Gause-Nilsson I; Xu J; Sonesson C; Johnsson E
J Diabetes Complications; 2017 Jul; 31(7):1215-1221. PubMed ID: 28284707
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Jabbour S; Seufert J; Scheen A; Bailey CJ; Karup C; Langkilde AM
Diabetes Obes Metab; 2018 Mar; 20(3):620-628. PubMed ID: 28950419
[TBL] [Abstract][Full Text] [Related]
20. Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.
Petrykiv S; Sjöström CD; Greasley PJ; Xu J; Persson F; Heerspink HJL
Clin J Am Soc Nephrol; 2017 May; 12(5):751-759. PubMed ID: 28302903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
